KPRX is the ticker symbol for KIORA PHARMACEUTICALS INC, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks KPRX with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is KPRX a good stock to buy?

KPRX is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/KPRX.

Where does 13F Pro source KPRX data?

All KIORA PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. KIORA PHARMACEUTICALS INC files with the SEC under CIK 1372514. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

KIORA PHARMACEUTICALS INC(KPRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

KIORA PHARMACEUTICALS INC (KPRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. KPRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $16.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), KIORA PHARMACEUTICALS INC reports net income of $-2.1M, free cash flow of $-1.9M. Top institutional holders of KPRX by reported 13-F value include PERCEPTIVE ADVISORS, ADAR1 Capital Management, CITADEL ADVISORS, based on the most recent SEC filings. KPRX trades on the Nasdaq exchange and files with the SEC under CIK 1372514. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KIORA PHARMACEUTICALS INC directly from SEC EDGAR.

Net Income

$-2.1M

Free Cash Flow

$-1.9M

KPRX key financials by period

KIORA PHARMACEUTICALS INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2024	10-K	$16.0M	$3.6M	28.1%
FY 2020	10-K/A	$12.1K	$-6.9M	—
FY 2019	10-K	$2.7M	$-7.1M	—
FY 2018	10-K	$1.7M	$-10.8M	—
FY 2017	10-K	$407.5K	$-13.2M	—
FY 2016	10-K	$669.3K	—	—

Institutions holding KPRX

Institutional investors reporting a position in KIORA PHARMACEUTICALS INC on SEC Form 13F.
Institution	Shares	Value	Reported
PERCEPTIVE ADVISORS	438,471	$1.2M	2026-06-30
ADAR1 Capital Management	167,941	$441.7K	2026-06-30
CITADEL ADVISORS	116,011	$305.1K	2026-06-30
TWO SIGMA INVESTMENTS	88,792	$233.5K	2026-06-30
MILLENNIUM MANAGEMENT	74,202	$195.2K	2026-06-30
HRT FINANCIAL	58,612	$154.0K	2026-06-30
RENAISSANCE TECHNOLOGIES	29,824	$78.4K	2026-06-30
GEODE CAPITAL MANAGEMENT	26,717	$70.3K	2026-06-30
VANGUARD CAPITAL MANAGEMENT	19,861	$52.2K	2026-06-30
Scientech Research	18,746	$49.3K	2026-06-30

SEC EDGAR: CIK 1372514 →

KIORA PHARMACEUTICALS INC

KPRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $16.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.